DLK1
MOLECULAR TARGETdelta like non-canonical Notch ligand 1
DLK1 (delta like non-canonical Notch ligand 1) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting DLK1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | tozasertib | 4.33 | 75 |
| 2 | bosutinib | 4.08 | 58 |
| 3 | neratinib | 3.66 | 38 |
| 4 | pelitinib | 3.50 | 32 |
| 5 | tae 684 | 3.43 | 30 |
| 6 | fedratinib | 3.40 | 29 |
| 7 | dovitinib | 3.09 | 21 |
| 8 | jnj 7706621 | 3.09 | 21 |
| 9 | lestaurtinib | 3.04 | 20 |
| 10 | kw 2449 | 2.64 | 13 |
| 11 | ast 487 | 2.56 | 12 |
| 12 | su 014813 | 2.20 | 8 |
| 13 | cep 1347 | 2.08 | 7 |
| 14 | Axitinib | 0.69 | 1 |
| 15 | Crizotinib | 0.69 | 1 |
About DLK1 as a Drug Target
DLK1 (delta like non-canonical Notch ligand 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented DLK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
DLK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.